Suppr超能文献

调查特发性肺纤维化(INSIGHTS-IPF)中的重要健康趋势:一项全国性前瞻性登记研究的原理、目的和设计。

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.

机构信息

Department of Internal Medicine V , Comprehensive Pneumology Center, University of Munich and Asklepios Fachkliniken München-Gauting , Munich , Germany.

Department of Respiratory Medicine , Hannover Medical School , Hannover , Germany.

出版信息

BMJ Open Respir Res. 2014 Jan 3;1(1):e000010. doi: 10.1136/bmjresp-2013-000010. eCollection 2014.

Abstract

BACKGROUND

Guidelines on the diagnosis and management of idiopathic pulmonary fibrosis (IPF), a rare manifestation of chronic progressive fibrosing interstitial pneumonia, have been updated by ATS/ERS/JRS/ALAT in 2011. In Europe, data are limited on the characteristics and management of such patients.

METHODS/DESIGN: Investigating significant health trends (INSIGHTS)-IPF is a prospective observational longitudinal registry designed to describe the characteristics and management of newly diagnosed (incident) and prevalent patients with IPF on the long term. The registry uses a non-probability sampling approach to collect data on characteristics, therapeutic interventions, health-related quality of life and health economic parameters. At least 500 patients in ambulatory care will be included consecutively in about 30 centres. The study has been initiated in November 2012, and currently (December 2013) follows 344 patients. ClinTrials.gov identifier is NCT01695408.

DISCUSSION

INSIGHTS-IPF documents one of the largest IPF cohorts in Europe. The registry is expected to provide much-needed data on the characteristics and management situation of patients with IPF in Germany. It will allow comparisons with other countries. Gap analyses based on current guidelines for management of these patients will be possible.

摘要

背景

美国胸科学会/欧洲呼吸学会/日本胸科学会/拉丁美洲胸科学会于 2011 年更新了特发性肺纤维化(IPF)的诊断和管理指南,这是一种罕见的慢性进行性纤维性间质性肺炎表现。在欧洲,关于此类患者的特征和管理的数据有限。

方法/设计:调查重要健康趋势(INSIGHTS)-IPF 是一项前瞻性观察性纵向登记研究,旨在描述新诊断(新发)和已确诊的 IPF 患者的特征和长期管理。该登记采用非概率抽样方法收集特征、治疗干预、健康相关生活质量和健康经济学参数的数据。将连续纳入大约 30 个中心的 500 名以上门诊患者。该研究于 2012 年 11 月启动,目前(2013 年 12 月)正在随访 344 名患者。ClinicalTrials.gov 标识符为 NCT01695408。

讨论

INSIGHTS-IPF 记录了欧洲最大的 IPF 队列之一。该登记处有望提供德国 IPF 患者特征和管理情况的急需数据。它将允许与其他国家进行比较。基于当前管理这些患者的指南进行差距分析将是可能的。

相似文献

3
[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry].
Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27.
5
7
Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
Clin Respir J. 2012 Jul;6(3):131-43. doi: 10.1111/j.1752-699X.2012.00302.x.
8
Incidence of idiopathic pulmonary fibrosis in Korea based on the 2011 ATS/ERS/JRS/ALAT statement.
Int J Tuberc Lung Dis. 2015 Jun;19(6):742-6. doi: 10.5588/ijtld.14.0650.
9
Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry.
BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.

引用本文的文献

1
Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry.
ERJ Open Res. 2025 Jun 9;11(3). doi: 10.1183/23120541.00926-2024. eCollection 2025 May.
3
Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study.
Front Med (Lausanne). 2020 Nov 16;7:601279. doi: 10.3389/fmed.2020.601279. eCollection 2020.
4
Epidemiology and Clinico-radiological features of Interstitial Lung Diseases.
Pak J Med Sci. 2020 Mar-Apr;36(3):365-370. doi: 10.12669/pjms.36.3.1046.
7
The natural history of progressive fibrosing interstitial lung diseases.
Respir Res. 2019 Mar 14;20(1):57. doi: 10.1186/s12931-019-1022-1.
8
Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions.
Eur Respir Rev. 2018 Feb 7;27(147). doi: 10.1183/16000617.0076-2017. Print 2018 Mar 31.

本文引用的文献

1
[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry].
Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27.
2
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.
Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.
3
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
N Engl J Med. 2011 Sep 22;365(12):1079-87. doi: 10.1056/NEJMoa1103690.
4
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
5
[GOLDnet - focus on rare lung diseases].
Dtsch Med Wochenschr. 2011 Apr;136(13):p10. doi: 10.1055/s-0031-1271828. Epub 2011 Apr 1.
6
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
Eur Respir J. 2011 Feb;37(2):356-63. doi: 10.1183/09031936.00159709. Epub 2010 Jul 1.
7
The role of cardiac registries in evidence-based medicine.
Eur Heart J. 2010 Mar;31(5):525-9. doi: 10.1093/eurheartj/ehp596. Epub 2010 Jan 20.
9
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.
Respir Med. 2010 Feb;104(2):296-304. doi: 10.1016/j.rmed.2009.09.006. Epub 2009 Oct 7.
10
[Assessment of quality of life in health services research - conceptual, methodological and structural prerequisites].
Gesundheitswesen. 2009 Dec;71(12):864-72. doi: 10.1055/s-0029-1239516. Epub 2009 Oct 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验